Image pharmaphorum Editor Views & Analysis How will NICE fare in a post-Brexit world? NICE has a global reputation as a pioneering HTA – but is that influence at risk now that the UK has left the EU? Views & Analysis From representation to empowerment: Putting patients at the ... Experts from Vynamic discuss their vision for a future where patients are at the heart of medicine reimbursement in Europe – and provide actionable steps for achieving this. Views & Analysis Rethinking access barriers to innovation Market access issues don’t stop once a product has passed HTA – and this is especially true for disruptive therapies like ATMPs. Views & Analysis A year on: pandemic driven trends in HCP engagement IQVIA’s John Procter explores why the industry should be paying attention to the changing HCP customer experience in the wake of COVID-19. Load more results
Views & Analysis How will NICE fare in a post-Brexit world? NICE has a global reputation as a pioneering HTA – but is that influence at risk now that the UK has left the EU?
Views & Analysis From representation to empowerment: Putting patients at the ... Experts from Vynamic discuss their vision for a future where patients are at the heart of medicine reimbursement in Europe – and provide actionable steps for achieving this.
Views & Analysis Rethinking access barriers to innovation Market access issues don’t stop once a product has passed HTA – and this is especially true for disruptive therapies like ATMPs.
Views & Analysis A year on: pandemic driven trends in HCP engagement IQVIA’s John Procter explores why the industry should be paying attention to the changing HCP customer experience in the wake of COVID-19.
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
